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Abstract
Background: Pulmonary capillary hemangiomatosis (PCH) is an uncommon pulmonary disorder, with variable
clinical features depending on which lung structure is affected, and it is usually linked to pulmonary arterial
hypertension. Congenital PCH has been very rarely described and, so far, the only causative gene identified is
EIF2AK4, which encodes for a translation initiation factor. However, not all PCH cases might carry a mutation in
this gene.
Case presentation: We report the clinical and cytogenetic characterization of a patient (male, newborn, first child
of healthy non-consanguineous parents) died after three days of life with severe neonatal pulmonary hypertension,
due to diffuse capillary hemangiomatosis diagnosed post mortem.
Conventional karyotyping, Microarray-Based Comparative Genomic Hydridization (CGHa) and quantitative PCR were
performed. CGHa revealed a heterozygous chromosome 16q23.3q24.1 interstitial deletion, spanning about 2.6 Mb and
involving a FOXF1 gene enhancer. Quantitative PCR showed that the proband’s deletion was de novo. Microsatellite
analysis demonstrate that the deletion occurred in the maternal chromosome 16.
Conclusion: FOXF1 loss of function mutation have been so far identified in alveolar capillary dysplasia with
misalignment of pulmonary veins (ACD/MPV), a lung disease different from PCH. Our data suggest the hypothesis that
disruption of the FOXF1 gene enhancer could be a genetic determinant of PCH. Moreover, our findings support the
idea that FOXF1 is a paternally imprinted gene.
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Background
Pulmonary capillary hemangiomatosis (PCH) is a rare
disorder that was first reported in 1978, with less than a
few hundred nonrelated cases reported, so far [1]. The
PCH frequency within the general population is actually
unknown [2, 3]. PCH anatomopathological features are
pulmonary hypertension and excessive neovasculariza-
tion characterized by capillary-sized blood vessels within
the pulmonary interstitial tissue, vasculature, and air-
ways [4, 5]. Clinically, PCH cases are quite variable; also
because, this disease could mimic different lung diseases,
including pulmonary veno-occlusive disease, idiopathic
pulmonary arterial hypertension and atypical interstitial
lung disease [2]. Nowadays, the only genetic cause iden-
tified is a mutation in EIF2AK4 gene (Eukaryotic transla-
tion initiation factor 2 alpha kinase 4, in chromosome
15q15.1), which encodes for a translation factor [6].
However, not all PCH cases might carry a mutation in
this gene [2].
We report the clinical and genetic characterization of
a newborn male presenting early severe pulmonary
hypertension, due to a post-mortem diagnosis of PCH.
He carried a 2.6 Mb sized 16q23.3q24.1 deletion, as
demonstrated by CGHa. He displayed no additional
anomalies or malformations, and no familial occurrence.
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The patient was the first child of nonrelated healthy
parents with a negligible familial history. The patient
was a full term (41 weeks) male infant, born by in-
duced vaginal delivery to a 38-year old mother, whose
pregnancy was uneventful. Birth weight, length and
head circumference were 3340 gr, 50.2 cm and
34.0 cm, respectively. Apgar scores were 4-10-10.
After birth, since the patient did not show spontan-
eous breathing and was hypotonic, he was stimulated
and ventilated by ambu (FiO2: 0.4). Because he pre-
sented an increased O2-requirement after one hour of
life, he was subjected to oxygenation by FiO2 40 %.
Chest radiography showed widespread hypodiafania of
the right hemithorax. Blood tests were negative for in-
fection. Ultrasound revealed a normal brain anatomy,
with mild hyperechoic periventricular left rear. Ultra-
sonography was compatible with wet lung disease.
21 h after birth, the infant developed a deteriorating
respiratory distress and echocardiography documented
a severe pulmonary hypertension in the absence of
congenital structural abnormalities. He died at the
third day of life from respiratory distress, pulmonary
hypertension, heart failure and an extreme bradycar-
dia. The autopsy demonstrated a lung parenchyma
characterized by marked edema and stasis.
Materials and methods
Histology and immunohistochemistry
Tissue from autoptic lung samples were fixed in 4 % for-
malin for about 24 h. Fixed tissue was then paraffin em-
bedded and 4 μm slides were stained with hematoxilin and
eosin. Immunohistochemical stains for CD31 (1:200, clone
JC70A, Dako, Denmark), CD34 (1:50, clone QBEND10,
Dako, Denmark) and histochemical Masson’s trichrome
stain were performed for vascular pattern observation.
Cytogenetics and molecular genetics
Blood samples of proband and parents were obtained
after a signed informed consent. Parents informed con-
sent was also given to analyse their own genomes. We
explained that analysis of the parents would be useful to
better understand the proband results. When CGHa is
performed, obtaining blood samples from parents is part
of our standard care.
Conventional high resolution karyotyping (GTG band-
ing) was performed on proband blood lymphocytes fol-
lowing conventional procedures.
For CGHa analysis genomic DNA was isolated from an
EDTA peripheral blood sample using QIAamp Blood Midi
Kit according to the manufacturer procedure (Qiagen,
Hilden, Germany). Molecular karyotyping was performed
in accordance with the manufacturer procedure with an
180,000-oligonucleotide microarray (Sure Print G3 Hu-
man CGH Microarray Kit 180 k, Agilent Technologies,
Santa Clara, CA, USA). The genomic sample was labelled
and hybridized according with the Agilent Enzymatic La-
belling protocol. We used a male DNA Coriell GM10851
(Coriell Institute, Camden, NJ, USA) as a normal refer-
ence. CGH Agilent Genomic Workbench Lite Edition
6.5.0.18 software and UCSC hg19 assembly were used to
analyze the results. The presence of a copy number vari-
ation was defined by the presence of an abnormal log2
ratio for at least three contiguous oligonucleotides. The
presence of the deletion in our patient was confirmed by
quantitative PCR using 7300 Real Time PCR System (Ap-
plied BioSystems, Foster City, CA, USA) (data not shown).
Primers inside OSGIN1, EMC8, ZDHHC7 genes were
employed.
Microsatellites located into the deletion were ana-
lyzed by PCR and capillary electrophoresis sizing of
the products. Microsatellites were amplified using the
following primers:






The amplified products were analyzed by capillary
electrophoresis (3500 IDX sequencer, Life Technologies).
Results
Histopathological analysis of the lungs showed marks
of PCH (Fig. 1, panel a). Sections of the lung reveal
lobular architecture with acinar underdevelopment and
numerous dilated vascular channels within the thick-
ened septa. Reduced radial-alveolar count was detected,
reflective of decreased alveolarization. Air-blood bar-
riers were detected within the alveolar walls; however, a
rich, congested, proliferated capillary network was
present within interalveolar septa. This is associated
with some hemorrhage into the airspace as well as
some regions with large number of hystiocytes in the
airspaces. Preacinar and intra-acinar arteries had thick
smooth muscle medial coats and there was an exten-
sion of smooth muscle into the peripheral intra-acinar
arteries up to the alveolar wall level. In addition, a thick
collagen adventitial coat was present around the preaci-
nar arteries. These structural features, are reminiscent
of those present in persistent pulmonary hypertension
of the newborn. Abnormalities of pulmonary lymphatics
were not present. No pulmonary venous misaligment or
obstructive/occlusive changes are discerned. Immunohisto-
chemical analysis of CD31 demonstrates septal capillaries
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dilatation and proliferation (Fig. 1, panel b). Altogether,
these features indicate the presence of an intractable hyper-
tensive pulmonary vascular disease of the newborn consist-
ent with the morphologic characteristics of pulmonary
hemangiomatosis with structural abnormalities in preacinar
and intra-acinar pulmonary arteries (“post-resistant seg-
ment of the vasculature”).
Standard karyotyping showed no abnormalities (46,XY).
CGHa identified a submicroscopic deletion in 16q23.3q24.1
cytoband (deletion size 2.6 Mb) (Fig. 2). The deletion
spans from 83,676,990 to 86,292,585 bp, encompassing
LINC01082 and disrupting LINC01081, which are long
non-coding RNAs located in the FOXF1 tissue-specific
distant enhancer, mapping 0.3 Mb upstream FOX genes
cluster [7]. Positions are referred to Genome Assembly
hg19. In the Additional file 1: Table S1 all genes contained
in the deletion are listed. Among them, only the DNAAF1
gene deficiency is known to cause a lung disease, i.e. the
primary ciliary dyskinesia (or Karatgener syndrome), in
which, however, airways cilia, but not alveoli and their ves-
sels, are affected.
No other pathogenetic genomic imbalance was detected
in the proband sample. Deletions in this region have been
recently found in patients with Alveolar Capillary Dyspla-
sia with Misalignment of Pulmonary Veins (ACD/MPV)
[7]. In Fig. 3 are shown all deletions of the FOXF1 region
so far identified in patients with ACD/MPV. PCH and
ACD/MPV are two different diseases related to opposite
phenomena in lung development disruption. In fact, PCH
is characterized by capillaries proliferation in pulmonary
interstitium [4, 5], while in ACD/MPC immature lobular
development and reduced capillary density are present
[8, 9]. In our patient, acinar underdevelopment and de-
creased alveolarization were present, which are reminis-
cent of ACD/MPV. However, we did not find the other
typical feature of ACD/MPV, i.e. misalignment of pulmon-
ary veins, in our case. Instead, the major histological find-
ing of our patient was the capillary proliferation within
the interalveolar septa, which is typical in PCH.
By quantitative PCR, our patient parents were evalu-
ated: both subjects presented no abnormalities, thus sug-
gesting the de novo origin of the deletion.
It is known that the 16q23.3q24.1 region could be
subjected to parental imprinting; in fact, in ACD/
MPV, the deletion always occurs in the maternal
chromosome and the paternal allele is less expressed
than the maternal one [10]. Thus, in order to test
whether the 16q23.3q24.1 deletion occurred in the
maternal chromosome, a microsatellite analysis was
conducted inside the deletion. As shown in Fig. 4,
analysis of L17941 and L29692 microsatellites indi-
cate that the deletion indeed occurs in the maternal
chromosome.
Conclusion
The PCH histopathologic lungs features show a crowded
and congested alveolar capillary bed without pulmonary
venous misalignment and lymphatic alteration. The alveo-
lar capillary expansion is usually associated with intraal-
veolar hemorrhage [4, 5]. Based upon our microscopical
findings, our patient suffers of PCH with structural
abnormalities in preacinar and intra-acinar pulmonary
arteries, consistent with the morphologic characteristics
of persistent pulmonary hypertension of the newborn.
The radial-alveolar counts were reduced, reflective of
decreased alveolarization.
PCH is considered an underestimated pathology, because
it may mimic idiopathic pulmonary arterial hypertension,
pulmonary veno-occlusive disease, atypical interstitial lung
disease, misaligment of lung vessel and alveolar capillary dys-
plasia or congenital pulmonary lymphangectasia [2, 11–13].
Based on familial occurrence, it is possible that congenital
forms of this disease may have a genetic determination. Best
et al. [6] have shown the involvement of EIF2AK4 gene mu-
tations in PCH pathogenesis. However, it is likely that
EIF2AK4mutations do not account for all cases of PCH [2].
In our case, CGHa revealed a chromosome 16q23.3-
q24.1 deletion that disrupts the distant FOXF1 transcrip-
tional enhancer, which maps about 257 kb upstream to
the FOXF1 gene. In this enhancer are located two
Fig. 1 Microscopic evaluation of lung tissues. Panel a, histologic
image (Hematoxilin-Eosin, 20X) of lung autoptic sample showing
widespread proliferation of septal capillaries with extensive alveolar
hemorrhage, without a proliferation in septal, or lung bronchovascular
bundles. Panel b, CD31 endothelial immunostaining (20X) demonstrates
marked septal capillaries dilatation and proliferation
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Fig. 3 Deletions associated with PCH and ACD/MPV. The map of the FOXF1 region is represented at the top: the FOXF1 gene and the
long non-coding RNAs LINC01081 and LINC01082 are shown. The gray bar below indicates the deletion found in our PCH patients, while
black bars indicate deletions in patients with ACD/MPV so far found
Fig. 2 CGHa analysis. Panel a, CGH signals of patient’s chromosome 16. The deleted region is highlighted by a brown area. Panel b, chromosome
16 region containing the deletion. The deleted region is shown in red. Positions of FOX genes are shown in black. Positions of microsatellites
LINC01081 and LINC01082 utilized for analysis are shown in green. Location of genes utilized for quantitative PCR are shown in blue. Base-pairs
are numbered according to hg19
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lncRNAs: LINC01081 and LINC01082 [7]. It has been
demonstrated that in vitro abolition of LINC01081 by
siRNA, reduces FOXF1 expression [14]. Thus, our data
could suggest that the disruption of the FOXF1 gene
transcriptional enhancer induces cell proliferation and
migration. This is consistent with other findings indicat-
ing FOXF1 as an oncosuppressor gene [15, 16]. The ana-
lysis of fusion progeny between mesenchymal stem cells
and lung cancer cells has recently demonstrated that
FOXF1 significantly reduced the growth rate and expres-
sion levels of proteins regulating the cell cycle [17]. Ac-
cordingly, previous investigations have proposed PCH to
be a lung endothelial neoplasia [18]. Based upon the
relevance of LINC01081 on FOXF1 expression regula-
tion, our data could suggest that the disruption of this
long non-coding RNA can lead to architectural changes
in pulmonary vessels, resulting in neonatal-onset PCH.
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